免费电话：400-668-6834 | 技术支持：400-168-6834 | 邮箱：info@selleck.cn

Barasertib (AZD1152-HQPA)

目录号：S1147 别名: AZD2811, INH-34, Barasertib-HQPA , Defosbarasertib 中文名称：巴拉塞替

仅限科研使用

Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) 是一种高度选择性的Aurora B抑制剂，无细胞试验中IC50为0.37 nM，作用于Aurora B比作用于Aurora A选择性高3700倍左右。

Barasertib (AZD1152-HQPA) Chemical Structure

CAS: 722544-51-6

规格	价格	库存
10mM (1mL in DMSO)	RMB 1375.46	现货
5mg	RMB 976.12	现货
25mg	RMB 3169.53	现货
大包装	有超大折扣
大剂量询单有大折扣!
今日订购，明日送达全国免运费分装免费分装成小规格产品（单支最小为1mg）如1支10mg产品可分装为10支1mg产品全国免费电话：400-668-6834 \| Email：info@selleck.cn

客户使用Selleck生产的Barasertib (AZD1152-HQPA)发表文献104篇：

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述

靶点

Aurora B ^[1]
(Cell-free assay)

0.37 nM

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

LNCaP	NHr0VIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFX6eIkxNTVyMDDuUS=>	M3L5UlQ5yqCq		MXLJR\|UxRTJ3IH7N	Mn25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e2OVkoRjJ3Mke3OlU6RC:jPh?=
LNCaP	NWfpb5lNSXCxcITvd4l{KEG\|c3H5	MX6wMVUxOCCwTR?=	NFLDPYo1QMLiaB?=		MoPNbY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bEB1cHKxdXfoJINie3Cjc3WtN{B2eHKnZ4XsZZRqd25?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{[1PUc,OjV{N{e2OVk9N2F-
LNCaP	MVPGeY5kfGmxbjDBd5NigQ>?	NFvGOGo2OCCwTR?=	M{DRU\|Q5KGh?		MlS0bY5lfWOnczDtbYNzd263Y3zlbUB4cXSqIHHu[ZVo\W6rYzDt[YNp[W6rc32=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{[1PUc,OjV{N{e2OVk9N2F-
Ramos	MVfGeY5kfGmxbjDBd5NigQ>?	NYDkO2FsPTByIH7N	NXXEfmFJOC15MjDo		NWHwV4ZPcW6qaXLpeJMhSXW{b4LhJGIhc2mwYYPl	NHuw[4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO\|E1PDZ:L3G+
Daudi	MXvGeY5kfGmxbjDBd5NigQ>?	MUG1NFAhdk1?	MUmwMVczKGh?		NFzE[Y5qdmirYnn0d{BCfXKxcnGgRkBscW6jc3W=	NIjNOoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO\|E1PDZ:L3G+
L540	MmPjSpVv[3Srb36gRZN{[Xl?	NVXLUJYyPTByIH7N	M{fxO\|AuPzJiaB?=		MUnpcohq[mm2czDBeZJwemFiQjDrbY5ie2V?	MlziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
BJAJ	NIPrPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rCeFUxOCCwTR?=	M2DFN\|AuPzJiaB?=		MWLpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF\|N{G0OFY9N2F-
Ramos	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITxboI2ODBibl2=	NH;0fY8xNTd{IHi=		MUnpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF\|N{G0OFY9N2F-
Raji	NFvZN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXqOVAxKG6P	NIrQb2gxNTd{IHi=		M33HfIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm=	NUL6fFZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO\|E1PDZpPkKxN\|cyPDR4PD;hQi=>
Daudi	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXi1NFAhdk1?	NILiVIkxNTd{IHi=		NI\vTldqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|aXfubYZq[2GwdHz5	M{PYdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
L428	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ryN\|UxOCCwTR?=	NV30NJJHOC15MjDo		NYrGTYRqcW6qaXLpeJMh[2WubDDndo94fGh?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF\|N{G0OFY9N2F-
KM-H2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vsdlUxOCCwTR?=	Mn7yNE04OiCq		MlTybY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NVHTV5pRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO\|E1PDZpPkKxN\|cyPDR4PD;hQi=>
HDLM-2	NVfqVWxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HiO\|UxOCCwTR?=	MWqwMVczKGh?		MnrjbY5pcWKrdIOgZ4VtdCCpcn;3eIg>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF\|N{G0OFY9N2F-
L450	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTUOVAxKG6P	MoPINE04OiCq		Ml;VbY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NVTLXWZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO\|E1PDZpPkKxN\|cyPDR4PD;hQi=>
BJAJ	NWTnUZpmSXCxcITvd4l{KEG\|c3H5	MkTyOVAxKG6P	NVr4bWZlOC15MjDo		M{f2[Ylv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy	M3XEelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
Ramos	NV7sOldySXCxcITvd4l{KEG\|c3H5	NFH2SGM2ODBibl2=	MlPvNE04OiCq		MX\pcoR2[2W\|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	NXT6UI15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO\|E1PDZpPkKxN\|cyPDR4PD;hQi=>
Raji	MXfBdI9xfG:\|aYOgRZN{[Xl?	NYW3VHNrPTByIH7N	M2LtPFAuPzJiaB?=		M3;5Wolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy	MoG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Daudi	M3nDTGFxd3C2b4Ppd{BCe3OjeR?=	MXy1NFAhdk1?	MX6wMVczKGh?		MWjpcoR2[2W\|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	M{fO[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
L428	NHHRW3JCeG:ydH;zbZMhSXO\|YYm=	NEnaZ4g2ODBibl2=	MnX4NE04OiCq		NX7JNHdpcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	NHHLbXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO\|E1PDZ:L3G+
KM-H2	MljERZBweHSxc3nzJGF{e2G7	Mny4OVAxKG6P	NWrme2txOC15MjDo		MWrpcoR2[2W\|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	NXO3UmNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO\|E1PDZpPkKxN\|cyPDR4PD;hQi=>
HDLM-2	M1q0fWFxd3C2b4Ppd{BCe3OjeR?=	NIPrUoU2ODBibl2=	Ml\5NE04OiCq		NUTzVXFXcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	NEf3c2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO\|E1PDZ:L3G+
L450	NGn4WJFCeG:ydH;zbZMhSXO\|YYm=	MX61NFAhdk1?	Mmm5NE04OiCq		MoLNbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	NYPCO5pQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO\|E1PDZpPkKxN\|cyPDR4PD;hQi=>
SW620	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrNd4RGSzVyPUGwxtEzNjFibl2=	NGDaRm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK0OVA6OCd-MkGyOFUxQTB:L3G+
HCT116	MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDFR\|UxRTFzwsGzMlMhdk1?	NH2xblk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK0OVA6OCd-MkGyOFUxQTB:L3G+
MDA-MB-435	M2PGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXG0eoxtOC1zMECwNEBvVQ>?	NH3FT\|UzNTViZB?=	NY\wd5JVTE2VTx?=	M4XSOGlEPTB;MUK1JI5O	M4nsTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
MDA-MB-468	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLnfXlHOC1zMECwNEBvVQ>?	M2n3OVIuPSCm	NXq0U2gxTE2VTx?=	M3vCdmlEPTB;MUSgcm0>	M1nvWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
MDA-MB-231	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\1epI2OC1zMECwNEBvVQ>?	NXXTV5c5Oi13IHS=	M4PnWGROW09?	MVXJR\|UxRTFyNTDuUS=>	MnTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzN{W5NlYoRjJyMUe1PVI3RC:jPh?=
BT474	NXHoU\|BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDOTGZFOC1zMECwNEBvVQ>?	NXPVXHhkOi13IHS=	NVTtZW9STE2VTx?=	NU\zTXU5UUN3ME24JI5O	NEDhV\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO\|U6OjZ:L3G+
MDA-MB-361	NHzCclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoP3NE0yODByMDDuUS=>	NXzZbJRlOi13IHS=	MmnRSG1UVw>?	NEnxUmhKSzVyPUewJI5O	NVnRcXBHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO\|U6OjZpPkKwNVc2QTJ4PD;hQi=>
HER18	M3iyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3[yblAuOTByMECgcm0>	M3XPR\|IuPSCm	M135WGROW09?	MXzJR\|UxRTJyIH7N	M4PHRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
HER18	M3nJNGFxd3C2b4Ppd{BCe3OjeR?=	MXGxNFAhdk1?	NV3JOmNROC9{ND:0PEBp	M4LQbWROW09?	NIDtOmdqdmS3Y3XzJIFxd3C2b4Ppd{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIDveIVvfGmjbB?=	Mnn2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzN{W5NlYoRjJyMUe1PVI3RC:jPh?=
MDA-MB-231	NXG5T\|JxSXCxcITvd4l{KEG\|c3H5	NUfJRmdoOTB3IH7N	M1rWeFAwOjRxNEigbC=>	MYXEUXNQ	M4q1OIlv\HWlZYOgZZBweHSxc3nzJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNicH;0[Y51cWGu	NGSxcYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO\|U6OjZ:L3G+
JHH-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWWwMlPjiJNzMECwxsBvVQ>?	M4jZflczKGh?		NVvEWIo5TUN3ME2xO{41yrFzLkCgcm0>	MnTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N\|UoRjF7OUGzPVM2RC:jPh?=
JHH-2	NGnifFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTKNJNSOC5\|4pETNVAxOMLibl2=	NVnySllSPzJiaB?=		NVe2[G9UTUN3ME2yNVgvOMLzMUCuPEBvVQ>?	MkTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N\|UoRjF7OUGzPVM2RC:jPh?=
JHH-4	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIix[4ExNjQkgKOxNFAxyqCwTR?=	MkT0O\|IhcA>?		M1vSSGVEPTB;MUW1MlbDuTF4Lkigcm0>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N\|U9N2F-
HuH-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHH5eXMxNjQkgKOxNFAxyqCwTR?=	M2fDd\|czKGh?		M1TXfWVEPTB;MkeuN:KyPS5yIH7N	NGLydJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN\|k{PSd-MUm5NVM6OzV:L3G+
HuH-6	MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELuNmcxNjQkgKOxNFAxyqCwTR?=	M{jsVFczKGh?		MVHFR\|UxRTNwN9MxNE43KG6P	M2\YVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN\|k{PTxxYU6=
HuH-7	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2wMlPjiJNzMECwxsBvVQ>?	NFraNIk4OiCq		MVvFR\|UxRTZwONMxNE4{KG6P	Mk\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N\|UoRjF7OUGzPVM2RC:jPh?=
HLE	M{LhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rQVlAvO+LCk{GwNFDDqG6P	MYK3NkBp		M3nwV2VEPTB;NEWuPeKyPi52IH7N	NYqyOG5uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HLF	M3O0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33VUFAvO+LCk{GwNFDDqG6P	NFqzVII4OiCq		NUfKc2Y2TUN3ME2xNlYvOcLzMUKuNkBvVQ>?	M1zSV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN\|k{PTxxYU6=
PLC/PRF/5	M1\Vemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXXVZk{OC5\|4pETNVAxOMLibl2=	NUL0OIY2PzJiaB?=		MnjKSWM2OD15Nj65xtE6Njlibl2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N\|U9N2F-
SK-Hep1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\uUFAvO+LCk{GwNFDDqG6P	NHzFeYw4OiCq		M3rjSWVEPTB;MkGuPeKyOS5{IH7N	M3TLNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN\|k{PTxxYU6=
Hep3B	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHDZYMxNjQkgKOxNFAxyqCwTR?=	MnjtO\|IhcA>?		MUnFR\|UxRTdwNtMxNU4zKG6P	NHvHZoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN\|k{PSd-MUm5NVM6OzV:L3G+
HepG2	MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zHblAvO+LCk{GwNFDDqG6P	MkfqO\|IhcA>?		MUjFR\|UxRTF2LkhCtVEvPyCwTR?=	NYTFUG1iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
Ramos	NXPqUnNySXCxcITvd4l{KEG\|c3H5	MUeyOU82OC9zMECgcm0>	M4H1TlQ5KGh?		MV7pcoNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO=	NYHQN3FjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NlMyPjhpPkG5PFI{OTZ6PD;hQi=>
Daudi	Mn:yRZBweHSxc3nzJGF{e2G7	NGnveY4zPS93MD:xNFAhdk1?	MnzCOFghcA>?		NXzCUG1QcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKGOuZXH2[YQh\m:{bYOgc4YhWEGUUDDhcoQh[2G\|cHHz[UA{	NHHGXnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiyN\|E3QCd-MUm4NlMyPjh:L3G+
BALM-14	M{HyUGFxd3C2b4Ppd{BCe3OjeR?=	MVKxNk42NzJ3L{WwJI5O	M1nld\|Q5KGh?		Ml\6bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJINt\WG4ZXSg[o9zdXNib3[gVGFTWCCjbnSgZ4F{eGG\|ZTCz	Mn\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6MkOxOlgoRjF7OEKzNVY5RC:jPh?=
BALM-27	NVW2cFN4SXCxcITvd4l{KEG\|c3H5	Ml;tNVIvPS9{NT:1NEBvVQ>?	NV\sNmw3PDhiaB?=		MmPtbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJINt\WG4ZXSg[o9zdXNib3[gVGFTWCCjbnSgZ4F{eGG\|ZTCz	M4PEPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEKzNVY5Lz5zOUiyN\|E3QDxxYU6=
NB4	NY\tTVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;LVppFOC5yMT:wMlEwOSEQvF2=	NUf6NHhVPDhiaB?=		NYDBV5BZcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=>	MknWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|Nke0PFQoRjF6M{[3OFg1RC:jPh?=
HeLa	NILEWI5HfW6ldHnvckBCe3OjeR?=	MWKxJJVO	NGHtbJozPCCqcoO=		NFHEU41KdmirYnn0bY9vKG:oIHH1do9z[SCEIHH1eI9xcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{BifCBzIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6p	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW0PUc,OjB4OES1OFk9N2F-

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	AURKB / pSer10 Histone H3 / TP53 / CDKN1A / MYCN p53 / p21 / p-p38 / p38	26497213 24782314
Immunofluorescence	p21	24782314
Growth inhibition assay	Cell viability	26497213

溶解度（25°C）

体外


体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+40% PEG 300+2% Tween 80+ddH2O 点击购买： PEG300 Tween 80	7mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量	507.56
化学式	C₂₆H₃₀FN₇O₃
CAS号	722544-51-6
储存条件	3年	-20°C	粉状
储存条件	2年	-80°C	溶于溶剂

Download Barasertib (AZD1152-HQPA) SDF

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

临床试验信息

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03217838	Terminated	Drug: AZD2811\|Drug: Azacitidine\|Drug: Venetoclax	Acute Myeloid Leukaemia	AstraZeneca	November 27 2017	Phase 1\|Phase 2
NCT02579226	Completed	Drug: AZD2811	Advanced Solid Tumours	AstraZeneca	October 28 2015	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

* 姓名 请输入您的姓名

* 邮箱 请输入您的邮箱地址 请输入一个有效的邮箱地址

电话

* 留言内容 请写点东西给我们

常见问题及建议解决方法

问题 1:
Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

回答：
S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):